News Esperion and Daiichi Sankyo square up on Nexletol milestone Companies can't see eye to eye on the recently reported data from the CLEAR outcomes study.
News Nexletol shows CLEAR benefit in cardiovascular outcome trial Will a 13% improvement in MACE over placebo be enough to lift lacklustre sales growth?
News FDA declines to approve AbbVie's Botox follow-up AbbVie's bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.